Enteric fever, encompassing both typhoid and paratyphoid fever, remains a significant health concern worldwide, particularly in developing countries. Rapid diagnosis and appropriate management are critical to reduce morbidity and mortality associated with this disease.
Traditional diagnostic methods, such as blood culture and Widal test, have limitations in terms of sensitivity, specificity, and turnaround time. Recent advancements have led to the development of molecular diagnostic tests like Polymerase Chain Reaction (PCR) and Nucleic Acid Amplification Tests (NAATs), which offer improved sensitivity and specificity, and faster results.
Increasing antimicrobial resistance, particularly to fluoroquinolones and third-generation cephalosporins, has complicated the management of enteric fever. This necessitates the use of culture and sensitivity tests to guide antibiotic therapy. Empiric treatment should now consider the local resistance patterns.
Vaccination plays a pivotal role in the management of enteric fever. The World Health Organization recommends the use of Ty21a and Vi polysaccharide vaccines in endemic areas. The newer conjugate vaccines, which have a longer duration of protection and can be given to younger children, are promising additions to the prevention strategy.
Supportive care, including hydration and antipyretics, remains a mainstay of treatment. In severe or complicated cases, hospitalization may be required. Post-treatment follow-up is crucial to ensure complete resolution of the disease and to monitor for potential complications.
An updated approach to the diagnosis and management of enteric fever includes the use of advanced diagnostic techniques, consideration of local antimicrobial resistance patterns, vaccination, and comprehensive patient care. As the disease landscape changes, it is essential for clinicians to stay informed about the latest developments to provide the best care for their patients.
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
The Growing Role of AI in Cancer Treatment
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
5.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
1.
Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
How Multidisciplinary Teams Support Modern Cancer Care
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation